The most successful cancer treatment of the past decade uses engineered immune cells — called CAR T-cells — that are programmed to hunt and destroy tumours. Scientists have now adapted that same approach for Alzheimer's disease, targeting the amyloid plaques that gradually destroy the brain.
The results, published in the journal Science in March 2026, are striking: a single injection of the new therapy completely prevented plaque formation in young mice, and cut existing plaque levels by approximately half in older mice already showing significant Alzheimer's pathology.
CAR-Astrocytes: Teaching the Brain to Clean Itself
The innovation comes from researchers at Washington University School of Medicine in St. Louis, led by professors Marco Colonna and David Holtzman. Instead of engineering T-cells (which don't normally live in the brain), they engineered astrocytes — the brain's most abundant support cells, which are naturally present throughout brain tissue.
They gave these astrocytes a chimeric antigen receptor (CAR) — a molecular "homing device" that instructs the cell to seek out, latch onto, and degrade amyloid-beta, the toxic protein that aggregates into the plaques that define Alzheimer's. The resulting CAR-astrocytes act as a "living drug": once introduced, they persist and keep working without further doses.
What the Mice Results Showed
In Alzheimer's mouse models, the effects were remarkable:
- In young mice, a single injection completely prevented amyloid plaque formation
- In older mice with existing plaques, a single injection reduced plaque levels by approximately 50%
- The therapy also protected neurons from damage and reduced neuroinflammation — a secondary driver of Alzheimer's that existing treatments don't address
Why This Is Different From Existing Treatments
Current FDA-approved Alzheimer's drugs — lecanemab (Leqembi) and donanemab (Kisunla) — also clear amyloid plaques. But they require frequent intravenous infusions at hospital facilities, typically every two to four weeks, and carry serious risks including brain swelling and bleeding.
The CAR-astrocyte approach, if it translates to humans, would offer a single injection with potentially lasting effect. The cells are delivered to the brain using a harmless virus — a gene therapy technique already in clinical use — and are designed to self-sustain.
"This 'living drug' paradigm could eliminate the need for repeated high-dose infusions," the researchers wrote — a significant advantage for both patients and the healthcare system.
The Road Ahead
This is preclinical research in mice, and the path from mouse model to human trial is long. The researchers acknowledge that further work is needed to optimise delivery, ensure long-term safety, and confirm that the approach translates to the more complex human brain.
But the principle — using the brain's own most abundant cells, armed with precision targeting technology, to clear its own debris — is elegant and scientifically sound. A patent has been filed. Human trials are the next step.
Alzheimer's disease affects more than 55 million people worldwide. For a condition where current treatments can only slow decline at best, a therapy that might one day prevent or dramatically reverse it represents exactly the kind of breakthrough those 55 million people — and their families — are waiting for.
Sources: Science (March 2026) · Washington University School of Medicine · SingularityHub · Neuroscience News · ScienceDaily · Technology Networks
